

Performance Against Delivery Benchmark

| Count | Research Ethics Committee Reference Number | Integrated Research Application System Number | Name of Trial | Target Number Of Patients Agreed? | Minimum Number Of Patients Agreed | Maximum Number Of Patients Agreed | Target Date To Recruit Patients Agreed? | Date Agreed to recruit target number of patients | Total Number Of Patients Recruited At The Agreed Target Date | Date That The Trial Closed To Recruitment | Total Number Of Study Participants Recruited | Reason For Closure |
|-------|--|---|--|-----------------------------------|-----------------------------------|-----------------------------------|---|--|--|---|--|----------------------|
| 1 | 18/SW/0050 | 235126 | A3921288 Phase 3B/4 Study of Tofacitinib in Subjects with UC | Number Agreed | 1 | 1 | Date Agreed | 30/04/2019 | 1 | 02/04/2019 | 1 | Recruitment Finished |
| 2 | 17/NI/0096 | 225743 | HOPE-1 | Number Agreed | 3 | 3 | Date Agreed | 30/04/2019 | 3 | 29/04/2019 | 3 | Recruitment Finished |
| 3 | 14/LO/0566 | 145475 | CANC - 3490 OLYMPIA | Number Agreed | 3 | 3 | Date Agreed | 30/04/2019 | 30 | 30/04/2019 | 30 | Recruitment Finished |
| 4 | 17/EE/0474 | 229785 | AdAPT: Adenovirus after Allogeneic Paediatric Transplantation | Number Agreed | 2 | 2 | Date Agreed | 31/05/2019 | 1 | 13/05/2019 | 1 | Recruitment Finished |
| 5 | 17/SW/0221 | 232448 | (CAIN457K2340) Secukinumab compared with GP2017 in Active AS | Number Agreed | 3 | 3 | Date Agreed | 30/06/2019 | 2 | 31/05/2019 | 2 | Recruitment Finished |
| 6 | 18/LO/1238 | 245332 | Open Label Extension study of WVE-210201 in patients with DMD | Number Agreed | 1 | 1 | Date Agreed | 30/06/2019 | 1 | 05/06/2019 | 1 | Recruitment Finished |
| 7 | 15/YH/0478 | 186697 | HEPA - 5032 The REGENERATE Study | Number Agreed | 2 | 2 | Date Agreed | 30/07/2019 | 3 | 17/06/2019 | 3 | Recruitment Finished |
| 8 | 18/LO/1311 | 248599 | GR40398 EFFICACY AND SAFETY OF RO6867461 IN DMO PATIENTS (RHINE) v1 | Number Agreed | 5 | 5 | Date Agreed | 30/11/2019 | 2 | 22/08/2019 | 2 | Recruitment Finished |
| 9 | 18/WS/0137 | 247036 | VISION Study of 177Lu-PSMA-617 in the treatment of PSMA-Positive mCRPC | Number Agreed | 6 | 6 | Date Agreed | 22/08/2019 | 3 | 29/08/2019 | 3 | Recruitment Finished |
| 10 | 19/EM/0003 | 251874 | Phase 3 Study of Edasalonexent in Duchenne Muscular Dystrophy | Number Agreed | 2 | 2 | Date Agreed | 30/06/2020 | 4 | 03/09/2019 | 4 | Recruitment Finished |
| 11 | 18/SC/0342 | 247085 | Phase III Trial of AMT-061 in adults with haemophilia B | Number Agreed | 1 | 1 | Date Agreed | 30/09/2019 | 0 | 03/09/2019 | 0 | Recruitment Finished |
| 12 | 18/WS/0172 | 251636 | 1011712 | Number Agreed | 5 | 5 | Date Agreed | 30/08/2019 | 0 | 04/09/2019 | 0 | Withdrawn By Sponsor |
| 13 | 16/LO/0543 | 198734 | GMP Drink for PKU Study | Number Agreed | 1 | 1 | Date Agreed | 31/12/2019 | 3 | 30/09/2019 | 3 | Recruitment Finished |
| 14 | 18/WM/0190 | 240027 | Combi-Aplus: Dabrafenib + Trametinib in BRAF+ve Melanoma | Number Agreed | 8 | 8 | Date Agreed | 29/08/2019 | 9 | 26/09/2019 | 9 | Recruitment Finished |
| 15 | 17/NW/0022 | 219189 | Post-Authorization Study of HyQvia in Pediatric PIDD subjects | Number Agreed | 2 | 2 | Date Agreed | 31/12/2019 | 5 | 22/10/2019 | 5 | Recruitment Finished |
| 16 | 17/YH/0392 | 230501 | BI 1467335 in patients with diabetic retinopathy. | Number Agreed | 2 | 2 | Date Agreed | 31/10/2019 | 2 | 31/10/2019 | 2 | Recruitment Finished |
| 17 | 19/EM/0047 | 257111 | GR40306 (TENAYA): A study of faricimab in nAMD | Number Agreed | 4 | 4 | Date Agreed | 31/12/2019 | 4 | 31/10/2019 | 4 | Recruitment Finished |
| 18 | 19/YH/0067 | 254066 | CANOPY-1 | Number Agreed | 3 | 3 | Date Agreed | 21/10/2022 | 0 | 05/12/2019 | 0 | Recruitment Finished |
| 19 | 19/NW/0482 | 269475 | Kepler | Number Agreed | 2 | 2 | Date Agreed | 30/03/2020 | 2 | 19/12/2019 | 2 | Recruitment Finished |
| 20 | 18/LO/1749 | 249644 | Efficacy and Safety of PF-04965842 in subjects aged 12 years and above, with Moderate-to-Severe AD | Number Agreed | 1 | 1 | Date Agreed | 05/04/2019 | 1 | 03/04/2019 | 1 | Recruitment Finished |
| 21 | 18/NE/0312 | 245315 | LTE Efficacy / Safety Study Of PF-04965842, w/wo T'cal Meds, in Subjs 12+ years with Mod to Sev AD | Number Agreed | 1 | 1 | Date Agreed | 07/07/2020 | 1 | 20/06/2019 | 1 | Recruitment Finished |
| 22 | 18/LO/0723 | 244615 | RPC01-3203:study of Ozanimod as Maintenance therapy for Crohns Disease | Number Agreed | 1 | 1 | Date Agreed | 28/02/2020 | 0 | 22/08/2019 | 0 | Withdrawn By Host |

Performance Against Delivery Benchmark

| Count | Research Ethics Committee Reference Number | Integrated Research Application System Number | Name of Trial | Target Number Of Patients Agreed? | Minimum Number Of Patients Agreed | Maximum Number Of Patients Agreed | Target Date To Recruit Patients Agreed? | Date Agreed to recruit target number of patients | Total Number Of Patients Recruited At The Agreed Target Date | Date That The Trial Closed To Recruitment | Total Number Of Study Participants Recruited | Reason For Closure |
|-------|--|---|--|-----------------------------------|-----------------------------------|-----------------------------------|---|--|--|---|--|----------------------|
| 23 | 18/LO/0722 | 238635 | A Phase 3 study of Ozanimod as induction therapy for Crohn's Disease | Number Agreed | 1 | 1 | Date Agreed | 01/09/2020 | 0 | 23/08/2019 | 0 | Withdrawn By Host |
| 24 | 18/LO/1223 | 244752 | RPC01-3204: Open Label Extension study of Ozanimod for Crohn's Disease | Number Agreed | 1 | 1 | Date Agreed | 30/11/2020 | 0 | 23/08/2019 | 0 | Withdrawn By Host |
| 25 | 18/EE/0378 | 248600 | Conbercept in Neovascular Age-related Macular Degeneration | Number Agreed | 5 | 5 | Date Agreed | 31/05/2020 | 11 | 18/12/2019 | 11 | Recruitment Finished |
| 26 | 18/LO/1450 | 248611 | Marigold Study 4407/0001 Marinus | Number Agreed | 4 | 4 | Date Agreed | 31/12/2019 | 5 | 31/12/2019 | 5 | Recruitment Finished |
| 27 | 17/SW/0174 | 228278 | A Phase 2 Clinical Trial in Patients with AML version amend 4 | Number Agreed | 1 | 1 | Date Agreed | 30/07/2021 | 1 | 06/01/2020 | 1 | Recruitment Finished |
| 28 | 17/LO/1476 | 224732 | A phase 2a Study in Adult Volunteers with Sickle Cell Anaemia - 001 | Number Agreed | 2 | 2 | Date Agreed | 17/01/2020 | 3 | 17/01/2020 | 3 | Recruitment Finished |
| 29 | 16/LO/0814 | 199311 | CHIL4593 - Sarilumab, administered with subcutaneous (SC) injection, in patients aged 2 to 17, with polyarticular-course juvenile idiopathic arthritis (pJIA) followed by an extension phase | Number Agreed | 1 | 1 | Date Agreed | 30/06/2020 | 0 | 27/01/2020 | 0 | Recruitment Finished |
| 30 | 16/LO/1960 | 199019 | CHIL4595 | Number Agreed | 1 | 1 | Date Agreed | 30/09/2019 | 0 | 27/01/2020 | 0 | Recruitment Finished |
| 31 | 19/YH/0099 | 257815 | LAT8881 in Neuropathic Pain | Number Agreed | 11 | 11 | Date Agreed | 31/03/2020 | 7 | 31/01/2020 | 7 | Recruitment Finished |
| 32 | 18/LO/1187 | 240011 | ATHENA - a first line ovarian cancer maintenance trial. | Number Agreed | 4 | 4 | Date Agreed | 30/04/2020 | 3 | 31/01/2020 | 3 | Recruitment Finished |
| 33 | 19/SC/0113 | 241916 | Idera 2125-MEL-301 | Number Agreed | 2 | 2 | Date Agreed | 31/12/2019 | 1 | 05/02/2020 | 1 | Recruitment Finished |
| 34 | 17/EM/0152 | 216307 | Post-transplant Gilteritinib maintenance in acute myeloid leukaemia | Number Agreed | 5 | 5 | Date Agreed | 15/02/2020 | 7 | 15/02/2020 | 7 | Recruitment Finished |
| 35 | 19/NI/0110 | 260538 | EluNIR HBR study | Number Agreed | 8 | 8 | Date Agreed | 31/07/2020 | 5 | 28/02/2020 | 5 | Withdrawn By Sponsor |
| 36 | 18/NW/0694 | 248847 | Derby - Geographic Atrophy secondary to AMD | Number Agreed | 2 | 2 | Date Agreed | 31/03/2020 | 1 | 13/03/2020 | 1 | Recruitment Finished |